Trai-Ming Yeh |
|
---|---|
¿ì¤½«Ç¹q¸Ü¡G |
5794 |
¿ì¤½«Ç¦aÂI¡G |
Âå§Þ¨tÀ]4¼Ó5794«Ç |
¹q¤l«H½c¡G |
|
¾Ç³N¦¨¤j¡G |
|
Publons¡G |
¤j¾Ç³¡
¤W¾Ç´Á
Á{§É¦å²M§K¬Ì¾Ç¹ê²ß
Âå¾Ç¥Íª«§Þ³N·§½×
¤U¾Ç´Á
Á{§É¦å²M§K¬Ì¾Ç
Á{§É¦å²M§K¬Ì¾Ç¹êÅç
ºÓ¤h¯Z
¤W¾Ç´Á
µL
¤U¾Ç´Á
µL
Potential
pathogenic roles of dengue nonstructural protein 1 (NS1) and its
antibodies in dengue virus infection
NS1 is involved in DENV replication within cells. The NS1 dimer can be anchored at the cell membrane or secreted out.
NS1 can bind to C4 protein and promotes its degradation.
NS1 can bind to prothrombin and inhibit its activation.
The binding of NS1 to cells may enhance endocytosis and cytokine production, which may increase vascular permeability. In the right panel,
anti-NS1 antibodies that cross-react with endothelial cells may induce endothelial damage.
Anti-platelet antibodies elicited by NS1 may inhibit platelet aggregation and cause thrombocytopenia. It is the integrated effects of NS1 and its antibodies, and the immunocomplexes they formed that may contribute to the development of thrombocytopenia, vascular leakage, and coagulopathy during the critical phase of DHF/DSS.
Macrophage
migration inhibitory factor (MIF)-induced autophagy plays important
role to cause vascular leakage during infection
³Õ¤h¯Z¡G
¡@¡@¡@Ĭ¡³s(88¯Å)¡B¶À¡³¼z(89¯Å)¡B³¯¡³«°(93¯Å)¡B²ø¡³¶v(101¯Å)¡B³¯¡³¦p(107¯Å)
¡@¡@¡@¿à¡³¥ò(108¯Å)¡B»¯¡³Þ±(109¯Å)¡B¹ù¡³½n(¸w·~)
ºÓ¤h¯Z¡G
¡@¡@¡@¼B¡³Á÷(83¯Å)¡BĬ¡³s(85¯Å)¡B¶À¡³¼z(85¯Å)¡B±`¡³¶Ç(87¯Å)¡BJ¡³¦w(88¯Å)
¡@¡@¡@³¯¡³°¶(89¯Å)¡B³¯¡³§D(¸w·~)¡B»¯¡³Å(91¯Å)¡B±ç¡³²b(92¯Å)¡B®]¡³³Ç(92¯Å)
¡@¡@¡@¯Î¡³îû(93¯Å)
¡BªL¡³±Ó(94¯Å)¡B¹ù¡³§ö(94¯Å)
¡B¹p¡³¯q(95¯Å)¡BÄÁ¡³Â{(97¯Å)
¡@¡@¡@²¡³¦t(97¯Å)
¡B²ø¡³¬w(97¯Å)¡B°ª¡³·u(98¯Å)¡B³\¡³¬Ñ(99¯Å)¡B±i¡³µx(99¯Å)
¡@¡@¡@ªô¡³(102¯Å)¡Bªô¡³¬Å(102¯Å)¡B¿à¡³¥ò(103¯Å)¡BªL¡³§g(103¯Å)¡B»¯¡³Þ±(104¯Å)
¡@¡@¡@Ù¡³°V(105¯Å)¡B§d¡³Àï(106¯Å)¡B§f¡³¸©(107¯Å)¡B³\¡³´@((108¯Å)¡B³¢¡³¤Ã(110¯Å)
¾Ç¤h¯Z¡G
ªL¡³·O(109¯Å)
|
©m¦W |
³sµ¸¤è¦¡ |
ºÓ¤G¥Í |
¾G¡³Õæ |
06-2353535#5794 |
ºÓ¤@¥Í |
¿c¡³»ö §º¡³®¦ |
06-2353535#5794 |
¤j¥| |
Á¡³¿« |
06-2353535#5794 |
§U²z |
³¯¡³´f |
06-2353535#5794 |
°ê¬ì·|¥ÒºØ¼ú§U(80-82¡B84-89¾Ç¦~«×)
°ê¬ì·|pµe¥D«ù¤H¶O¼ú§U (90-98¾Ç¦~«×)
¬ì§Þ³¡pµe¥D«ù¤H¶O¼ú§U (99-110¾Ç¦~«×)
1995 ¤¤µØ¥Á°ê·L¥Íª«§K¬ÌÂø»x¦~«×Àu¨}½×¤å
1997 ¤¤µØ¥Á°êÂå¨ÆÀËÅç¾Ç·|Á{§ÉÀËÅç¾Ç³N¼ú¤§§K¬Ì¦å²M¯f¬rÀË´úÃþ§O½×¤å¼ú
1997 ¦¨¤jÂå¾Ç°|¦~«×Àu¨}½×¤å
2004 ¤¤µØ¥Á°êÂå¨ÆÀËÅç¾Ç·|¾Ç³N½×¤å¼ú
2012 SysmexÂå¾ÇÀËÅç½×¤å¼ú
2014 Àò¿ï¦¨§öÂå¾Ç¤å±Ð°òª÷·|Àu¨q½×¤å¼ú
2015 SysmexÂå¾ÇÀËÅç½×¤å¼ú
2017 ¬ã¨s¦¨ªG ”µo®iµn²¯f¬r«Dµ²ºc©Ê³J¥Õ1¯Í»H°Ï°ì¬Ì]¤Î³æ®è§ÜÅé¹ï§Üµn²¯f¬r·P¬V”Àò¿ï¬ì§Þ³¡¥¼¨Ó¬ì§Þ®i
2018 Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability (Àò¼ú°]¹Îªk¤H¥xÆWÂå¨ÆÀËÅç¾Ç·|107¾Ç¦~«×¾Ç³N½×¤å¼ú°ò¦¬ã¨s²Õ)
2019 ºaÀòÂå¾Ç°|2018¦~³Ì¨Î½×¤å¼ú/·s¤H³Ì¨Î½×¤å¼ú
2019 ºaÀò¬ì§Þ³¡¡u108¦~«×³Ç¥X¬ã¨s¼ú¡v
2020 ¤j±M¥Í¤Î¬ã¨s¥Í¶Ç¬V¯f¨¾ªv¬ã¨sÀu¨qµÛ§@¼ú («ü¾É³Õ¤h¯Z¾Ç¥Í»¯¥©Þ±)
2020 °]¹Îªk¤H¦¨§öÂå¾Ç¤å±Ð°òª÷·|Àu¨q½×¤å¼ú
§Üµn²¼ö¯f¬r«Dµ²ºc©Ê³J¥ÕI¤§³æ®è§ÜÅé¤Î¨ä§@¥Î³~¡A¤¤µØ¥Á°ê±M§Q¸¹½X¡GI1511977¡A°ê§O:¥xÆW¡A±M§Q´Á:2015/12/11~2035/12/11
SYNTHETIC POLYPEPTIDE, VACCINE COMPOSITION COMPRISING THE SAME, AND USES THEREOF¡A¬ü°ê±M§QÁ{®É¸¹½X¡G62411493¡A°ê§O:¬ü°ê¡A±M§Q´Á: 2016/10/21
µû¦ôÓÅ餧µn²¼ö¯f¬r·P¬VÄY«µ{«×ªº¤èªk¡BÀË´ú¸Ë¸m¤ÎÀË´ú®M²Õ¡A¤¤µØ¥Á°ê±M§Q¸¹½X¡GI624668¡A°ê§O:¥xÆW¡A±M§Q´Á: 2018/05/21~ 2037/05/11
¦X¦¨¦h肽¡B¥]§t¸Ó¦X¦¨¦h肽¤§¬Ì]²Õ¦Xª«¤Î¨ä¥Î³~¡A¤¤µØ¥Á°ê±M§Q¸¹½X¡GI653049¡A°ê§O:¥xÆW¡A±M§Q´Á: 2019/03/11~ 2037/10/22